Compare stocks

Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.